Management of Spinal Stenosis in Psoriatic Arthritis

Assessment and Diagnosis

The American College of Rheumatology recommends evaluating spinal stenosis in psoriatic arthritis patients for inflammatory back pain features, including onset age <45 years, symptoms >3 months, morning stiffness >30 minutes, insidious onset, improvement with exercise, and alternating buttock pain 1
Assessment should include evaluation of limitation of motion in the cervical, thoracic, or lumbar spine and radiological criteria such as sacroiliitis, syndesmophytes, or MRI changes showing bone marrow edema 1
Disease activity in the spine can be measured using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), with active disease defined as a BASDAI score >4 1
Patients with PsA should be assessed for both axial and peripheral joint involvement, as they may present with various manifestations including inflammatory arthritis of the spine similar to ankylosing spondylitis 3

The European League Against Rheumatism recommends using NSAIDs as initial therapy for symptom control in mild to moderate spinal disease 1
Physical therapy is recommended as a first-line intervention to improve function and reduce pain 1
Education, analgesia, and consideration of sacroiliac joint injections should be included in the initial management approach 1
Local injections of glucocorticoids may be considered as adjunctive therapy for persistent inflammation 4

Traditional oral DMARDs (methotrexate, leflunomide, sulfasalazine) have not been shown to be effective for axial manifestations of PsA and should not be considered adequate for PsA axial disease 1, 5
For moderate to severe spinal disease with insufficient response to NSAIDs, TNF inhibitors should be considered 4, 1
If there is relevant skin involvement along with axial disease, an IL-17 inhibitor may be preferred over TNF inhibitors 4

Rheumatologists should primarily care for the musculoskeletal manifestations, but collaboration with a dermatologist is recommended when there is clinically significant skin involvement 6, 4
Treatment goals should focus on maximizing health-related quality of life through control of symptoms, prevention of structural damage, and normalization of function 6, 4
Comorbidities such as cardiovascular disease, metabolic syndrome, and depression should be taken into account when managing patients with PsA 6, 4

Treatment response should be assessed after 6 weeks using the BASDAI, with response defined as a BASDAI score <3 or a reduction by 2 points 1
Regular monitoring and appropriate adjustment of therapy should aim at reaching remission or low disease activity 6, 4
Poor prognostic factors include polyarticular disease, elevated inflammatory markers, previous treatment failures, existing joint damage, and diminished quality of life 2, 7

Uncontrolled arthritis can cause radiologic signs of joint damage in 50% of patients evaluated in tertiary care rheumatology centers 3
Comorbidities such as cardiovascular disease, metabolic syndrome, and depression should be taken into account when managing patients with PsA 6, 4